IIPR Stock: Tenant Defaults, Dividend vs AFFO, Series B Offering

What the October 9 filing is: a $50 million preferred stock offering, not notes

IIPR's list of recent SEC filings shows three 424B5 prospectus supplements since September: one on September 1, one on October 7 and one on October 9, 2026. The first, dated August 31, only reshuffled the sales agents on the company's $500 million at-the-market (ATM) program, which lets it sell common stock and its 9.00% Series A preferred at market prices; $336.9 million of capacity remained. The October 7 filing was the preliminary prospectus, with the size, rate and price left blank. The October 9 filing is the final prospectus for the Series B preferred. A pricing term sheet (Form FWP) is dated October 8.

Three details matter for a holder. First, the prospectus says dividends “will accrue whether or not (i) we have earnings” and whether or not they are declared, which is what “cumulative” means,. Second, the pricing term sheet states the annual dividend as “$2.13” per share, while the prospectus says $2.3125; 9.25% of $25.00 is $2.3125 (our arithmetic), so the term sheet figure looks like a typo, and the prospectus governs. Third, the term sheet says IIPR's Executive Chairman intends to buy 40,000 Series B shares at the offering price.

The company's earlier preferred stock is the benchmark: the Series A paid $0.5625 a quarter ($2.25 a year, 9.00%) and last traded at $25.02 on August 28, 2026, according to the September 1 supplement. At June 30, 2026 there were 5,666,082 Series A shares outstanding, and the same count was outstanding on September 30, so none was sold on the ATM in the third quarter (our reading of the two share counts).

A premise worth correcting: IIPR's debt in the news this year is not a new note in this filing. The notes in the capital structure are the 6.00% exchangeable senior notes due 2029 issued on June 15, 2026, covered below.

Tenants: who pays the rent

The 10-Q lists the five tenants with the largest share of rental revenue, including tenant reimbursements. Each includes affiliates with a parent guaranty.

A year earlier, The Cannabist Company was the fifth-largest tenant at 8% of Q2 2025 rental revenue across 21 leases. It is now 19 properties and 3.2% of annualized contractual rent, with a declared default and a Canadian creditor-protection filing. The largest single property, in New York, was 5.7% of net real estate at June 30, 2026, so the exposure is to operators rather than to one building.

Here is where the filings put each tenant that is not paying in full. “Annualized contractual rent” is IIPR's own base, and it is not the same as revenue.

Adding the three percentages the 10-Q gives as of June 30, 2026 (9.3% for 4Front and TILT, 6.0% for Cannabist and Battle Green, 6.1% for Parallel) gives 21.4% of annualized contractual rent (our arithmetic). That leaves out PharmaCann's occupied New York and Pennsylvania buildings, whose share the 10-Q does not give. It is also a count of leases that are in default or vacating, not a forecast of lost rent: some of that rent may be re-leased, and some arrives from deposits and court payments, as the next section shows.

Why Parallel has three percentages. The July 21 8-K says Parallel's two Florida properties were about 5.2% of “annualized contractual rent and income from loans and securities” and 5.7% of “annualized contractual rent” for the three months ended March 31, 2026. The 10-Q, filed two weeks later, gives 6.1% of annualized contractual rent as of June 30. The denominators and dates differ. The FY2025 10-K shows Parallel's two properties as 7% of contractual rent collected in 2025 ($16.1 million). Whichever you use, it is the largest single-tenant default declared in 2026 in the filings we read (our reading).

The portfolio counts show the effect of sales and terminations:

The June 30 figures are before the Parallel default on July 20. Future contractual minimum rent was $3.95 billion at June 30, including $286.9 million for 2027, but those are amounts tenants owe under leases, not amounts collected; several of the tenants above are not paying them.

The 10-Q does not soften the picture: “These tenant-related challenges are currently having a material adverse effect on the Company’s financial condition, results of operations, and cash flows.” It also says unfavorable market conditions have “adversely affected our ability to re-lease properties upon tenant defaults at the rental rates we currently receive.”

Rent that did come in: deposits and court payments

Two sources are cushioning the defaults: security deposits that IIPR applies to unpaid rent, and payments from defaulted tenants (court-escrowed rent and settlement payments).

The earnings release shows the Q1 and Q2 payments are mostly PharmaCann ($3.2 million, then $1.2 million) with a growing contribution from 4Front ($0.2 million, $0.7 million, then $0.4 million in early Q3). On the balance sheet, “rent received in advance and tenant security deposits” was $44.7 million at June 30, 2026 against $50.3 million at December 31, 2025, but that line mixes prepaid rent with deposits and the filings we read do not split it or state the deposit held for Parallel. In the July 21 8-K IIPR says it is holding deposits that “may be applied” to the July amounts.

The dividend against AFFO, as IIPR defines it

AFFO is the company's own measure, not a GAAP number. IIPR starts from net income, adds back real estate depreciation, impairments and losses on sales (FFO), then adds back litigation expense, income from seller-financed notes and deferred payments on sales-type leases (Normalized FFO), and finally adds back stock compensation and non-cash interest. “We calculate AFFO by adjusting Normalized FFO for certain non-cash items.” The 10-Q warns that “FFO and AFFO do not represent cash flow available for management’s discretionary use.” Per-share AFFO also leaves out the dilution from the exchangeable notes.

In dollars the picture is the same: Q2 2026 AFFO attributable to common stockholders was $53,009 thousand against $53,127 thousand of common dividends declared, and for the half-year $106,443 thousand against $107,573 thousand. AFFO attributable to common is already after the Series A preferred dividend ($3.187 million in Q2). The 2025 quarters were $1.94, $1.71, $1.71 and $1.88 of AFFO per share, so the Q2 2026 figure is within that range; what changed is that the dividend rose 1% in 2025 while AFFO fell 19%.

Two items point forward, and the filings give both sides only partly:

• A full quarter of exchangeable-note interest. Q2 AFFO included $1.0 million of cash interest on the notes, covering about two weeks after June 15. A full quarter of the 6.00% coupon on $402.5 million is about $6.0 million (our arithmetic), and the first payment is due December 15, 2026. The 10-Q does not show the interest earned on the cash raised, so we do not net it.
• More preferred. The Series B adds about $4.6 million a year before any over-allotment (our arithmetic), paid ahead of common holders.

The company did not cut the common dividend in the filings we read. The two 2026 declarations (March 13 and June 15) were $1.90 each. We have not found a Q3 declaration in the filings read as of October 14, 2026. At the $56.31 price quoted in the September 1 filing for August 28, 2026, $7.60 a year is 13.5% (our arithmetic); that is the price in the filing, not a current quote, and we take no view on it.

Debt: from the 2026 notes to the 2029 exchangeable notes

The FY2025 10-K, filed in February 2026, said management “has concluded that there is substantial doubt about the Company’s ability to continue as a going concern” because $291.2 million of 5.50% notes were due in May 2026. The 10-Q says that doubt “has been resolved” after the notes were repaid at maturity: $9.1 million early in April and $282.1 million in May. The money came from term loans and, on June 15, 2026, a private sale of 6.00% exchangeable notes.

By year, principal falls due as follows (10-Q table, $ million): 2026, $0.6; 2027, $1.2; 2028, $93.8; 2029, $478.9; 2030, $1.0; thereafter $48.0. The 2029 figure is $402.5 million of exchangeable notes plus $76.4 million of term loans, 77% of the total (our arithmetic). The revolving facility matures on October 23, 2026, nine days after this page's date, with nothing drawn at June 30; the 10-Q does not say whether it will be renewed.

At the exchange price of $69.39, the notes would turn into about 5.8 million shares, 21% of the 27.57 million common shares outstanding at June 30 (our arithmetic from 14.4113 shares per $1,000). That price is 23% above the $56.31 quoted for August 28, 2026 (our arithmetic). IIPR also used $80.5 million of the proceeds to buy back 1,334,466 shares concurrently from note purchasers, part of 1,468,542 shares ($89.0 million, an average of $60.58) repurchased in Q2.

Company-reported leverage was low at June 30: net debt to total gross assets 14.2% (gross assets $3.0 billion), net debt to adjusted EBITDA 1.7 times, total liquidity $299.7 million including $204.7 million of cash. The Series B ranks behind all of it.

IQHQ: the other half of the story

IIPR's second business is lending to and investing in IQHQ, a private life-science real estate company. The 10-Q shows $270.0 million in two pieces, both fully funded by June 30, 2026, and the 8-K of October 1 adds a third.

On the filings' figures, IIPR had put $381.0 million into IQHQ by the end of September (our arithmetic: $270.0 million plus $111.0 million) with $134.0 million of its $245.0 million mezzanine commitment unfunded (our arithmetic). The Series B proceeds of about $48.1 million are aimed at that unfunded amount; the loan agreement ties the remaining draws to conditions including construction budgets and the absence of defaults. The 10-Q shows life-science investments of $275.9 million at June 30, 10.7% of $2,581.6 million of total assets (our arithmetic), producing $8.5 million of Q2 interest and dividend income, 14% of segment net income (our arithmetic). It recorded no allowance for credit losses on the credit facility, with fair value assessed at a 16.6% market yield. The Alewife loan pre-dates IIPR's role in it (the original agreement is dated January 26, 2024, with a maximum of $218.0 million). For how another vehicle that holds IQHQ marks its position, see our read of NexPoint's IQHQ concentration.

Impairments, non-accruals and the loans

The 10-Q reports no impairment losses in the first half of 2026. The last was $3.5 million in the first half of 2025 on a Palm Springs, California property. Other credit items in the same filings:

• A construction loan of $22.8 million on a California cultivation facility, with interest recognized only when received (cash basis) and no allowance recorded; the borrower extended its maturity to December 31, 2026.
• A $49.0 million seller-financed loan from selling a New York property in May 2026 for $88.5 million ($39.5 million in cash). IIPR booked a $16.7 million gain, and the loan matures on May 25, 2027 with two one-year extensions. Seller financing was 55% of the price (our arithmetic). That gain is excluded from AFFO.
• A $16.1 million secured note declared in default in 2025 (the “MIH Note,” per the 10-K).
• Notes receivable of $16.8 million whose fair value used expected market yields averaging 33.0% (26.5% at December 31, 2025), a sign of how the company itself prices the risk on that piece.

Lawsuits and the SEC investigation

On February 13, 2026, IIPR was notified that the SEC is conducting a formal investigation concerning matters “generally similar” to those alleged in a pending securities class action in the U.S. District Court for the District of Maryland (Case No. 1:25-cv-00182-RDB), and it received a subpoena from the SEC's Denver Regional Office. The company says it will cooperate and that “a loss is neither probable nor estimable.” The class action, brought on behalf of buyers of the stock between February 2024 and March 2025, was dismissed without prejudice on May 27, 2026; the plaintiff filed a second amended complaint on June 26, 2026. These are allegations that have not been proven, and several related derivative suits are stayed or pending. An earlier securities case was dismissed with prejudice in 2024 and the dismissal was affirmed on appeal in October 2025.

What a holder or buyer can do with this

This page is analysis of public documents, not investment, legal or tax advice. What the filings let you check yourself:

• Test the dividend against both measures. AFFO was $1.83 against $1.90 in Q2, and operating cash flow trailed dividends paid in the first half. Whether $7.60 holds depends on re-leasing the Parallel, 4Front and PharmaCann buildings, which is not decided in the documents.
• Track the dated events. The revolving facility matures October 23, 2026. The Series B settles October 19 and its first dividend is January 15, 2027. The first exchangeable-note coupon is December 15, 2026. The 4Front receivership is expected to end by year-end 2026 or early 2027, and the New York and Pennsylvania PharmaCann license transfers are described as near-term.
• Watch the Parallel buildings. The Q3 10-Q should say whether the two Florida properties were surrendered, re-leased or put up for sale, and what deposits covered.
• Separate the two businesses. Cannabis rents are the dividend's base. IQHQ interest and preferred dividends are now a visible part of income, and part is paid in kind rather than in cash (1.5% on the loan, 5.0% on the preferred).
• Compare with other listed lenders and REITs. Arbor Realty Trust's dividend cuts and delinquencies show how one issuer's dividend moved against the earnings measure it uses; how non-traded REITs differ from publicly traded ones covers the exit difference if you also hold a private vehicle.

We do not cover how cannabis rescheduling affects anyone's taxes or licenses; the 10-Q describes the April 2026 federal order and the pending hearing process, and we leave those questions to the filings and to qualified advisers.

FAQ

All figures are from Innovative Industrial Properties, Inc. (CIK 1677576) SEC filings read on EDGAR on October 14, 2026: Form 10-K for 2025 (accession 0001677576-26-000001, filed February 24, 2026); Form 10-Q for the quarter ended June 30, 2026 (0001677576-26-000004); Form 8-K of July 21, 2026 on Parallel (0001104659-26-085238); Form 8-K of August 3, 2026 with the second-quarter earnings release as Exhibit 99.1 (0001677576-26-000003); the September 1, 2026 424B5 on the ATM program (0001104659-26-103972); Form 8-K of October 1, 2026 on the Alewife mezzanine loan (0001104659-26-112568); the October 7 preliminary 424B5 (0001104659-26-114219), the October 9 final 424B5 (0001104659-26-115075) and the pricing term sheet FWP (0001104659-26-114803). Sums, percentages, payouts, ratios and implied share counts are our arithmetic. Litigation claims are allegations. Shares of IIPR and its preferred stock trade on the NYSE; prices quoted are those printed in the filings on the dates given and are not current. This is analysis of public documents, not investment, legal or tax advice.